Intarcia inks antibody deal with Numab; Sanofi moves toward GLP-1 filing;

@FierceBiotech: ICYMI: Retrophin bags rare disease approval, FDA voucher in $75M deal. Article | Follow @FierceBiotech

@JohnCFierce: The interesting headline on the top revenue report, $LLY gets nudged out of top 10 by a booming $GILD--$LLY now #14. FiercePharma feature | Follow @JohnCFierce

@DamianFierce: Here are some particularly tight #FierceMadness matchups in Round 1. Cast your votes here | Follow @DamianFierce

> Intarcia Therapeutics partnered up with Switzerland's Numab to develop new antibodies for metabolic and autoimmune diseases, paying an undisclosed up-front payment to expand its pipeline beyond the Phase III ITCA 650. More

> AbbVie ($ABBV) signed a deal with C2N Diagnostics to get its hands on some anti-tau protein antibodies for Alzheimer's disease. News

> Amgen ($AMGN) submitted evolocumab, its PCSK9-blocking treatment for high cholesterol, for Japanese approval. Item

> Sanofi ($SNY) says its GLP-1 diabetes drug lixisenatide didn't increase cardiovascular risks in a late-stage outcomes study, clearing the way for an FDA submission. Story

Medical Device News

@FierceMedDev: Roche joins forces with Sigma-Aldrich to distribute biochemical reagents. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: I'm going to skip work and fill out my #FierceMadness bracket at the bar! Check it out | Follow @VarunSaxena2

@EmilyWFierce: Merck KGaA to tap Oschmann as new CEO, sources report. Article | Follow @EmilyWFierce

> Philips to help fund HealthTech refocus with 2016 lighting biz IPO. Story

> GE tech hub develops innovative handheld probe for bedsore monitoring. Article

Pharma News

@FiercePharma: Remember, you can keep on voting in #FierceMadness Round 2 all through the weekend. Vote | Follow @FiercePharma

@EricPFierce: India's Micro Labs, whose Bangalore plant was banned by FDA, is recalling simvastatin made at Goa facility. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Another reason to vote in #FierceMadness: Once you do, you can see others' comments, which so far have proven to be my favorite thing ever. | Follow @CarlyHFierce

> GSK's Breo for asthma? FDA panel says yes--but only in adults. News

> Merck KGaA to tap Oschmann as new CEO, sources report. Report

> Judge says Novartis can launch biosimilar of Amgen's Neupogen. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.